News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Serologicals Corporation's (SERO) Research Division, CHEMICON International Enters Into Exclusive License Agreement With Genome BioSciences Inc.

10/19/2005 5:10:48 PM

TEMECULA, Calif.--(BUSINESS WIRE)--Nov. 18, 2003--Chemicon International, Inc. ("Chemicon"), a division of Serologicals Corporation (NASDAQ/NM: SERO - News), today announced that it has entered into an exclusive licensing agreement with Genome BioSciences, Inc. for the use and application of Genome BioSciences' patent pending Positive - Positive Selection gene targeting technology. Under the terms of the agreement, Chemicon will have the exclusive right to utilize the technology for generating genetically modified cell lines and mice for its customers. In addition, Chemicon will retain exclusive rights to grant third party technology sublicenses. The Positive - Positive Selection gene targeting technology represents the first in a series of platform technologies expected to be licensed by Chemicon for the establishment of a new functional genomics initiative focused on the development and marketing of products and custom services centered around defining gene function. Dr. Rob Burgess, Genome BioSciences President, will join Chemicon as Senior Director of Functional Genomics and will oversee the implementation of gene targeting and other genomics initiatives, while remaining a director of Genome BioSciences.

"The acquisition of Genome BioSciences' gene targeting technology complements our current position of being the leading provider of mouse ES cell culture supplements for gene targeting and also broadens our product offerings in functional genomics research and drug discovery," said Jeffrey D. Linton, President of CHEMICON. "This agreement represents another example of Chemicon's strategy of leveraging our core competencies, through a combination of licensing and in-house development efforts, to continue to introduce leading edge products and technologies to the medical research community."

"We are pleased that the alliance between Genome BioSciences and Chemicon has evolved to this extent and is now the driving force behind Chemicon's functional genomics efforts," stated Dr. Burgess. "This agreement will broaden the access that researchers around the world have to Positive - Positive Selection gene targeting products, mouse disease-model development services and related technology."

About Serologicals and Chemicon

Serologicals Corporation, headquartered in Atlanta, Georgia, is a global provider of biological products and enabling technologies, which are essential for the research, development and manufacturing of biologically based life science products. Customers include many of the leading research institutions and life science companies throughout the world. The Company's products and technologies are used in a wide variety of innovative applications within the areas of neurobiology, cell signaling, cancer, angiogenesis, apoptosis, developmental biology, cellular physiology, oncology, hematology, immunology, cardiology, infectious diseases, and molecular biology. Through its Chemicon Division, the Company also manufactures diagnostic products at its cGMP, ISO, and TGA approved facilities. Chemicon International, Inc., a wholly owned subsidiary of Serologicals Corporation, is headquartered in Temecula, California. Serologicals has more than 800 employees worldwide, and its shares are traded on the NASDAQ national stock market under the symbol SERO. For more information on Serologicals Corporation and Chemicon International, visit the companies' web sites at and

Serologicals is a registered trademark of Serologicals Royalty Company.


Serologicals, Atlanta Chemicon International, Inc. Roy Millender, 909/676-8080 or

Genome Biosciences David Beckman, 909/699-8510 ext. 501

Source: Serologicals Corporation

Read at

Related News

comments powered by Disqus